Japan· JP-1190405G1024
オファツムマブ（遺伝子組換え）
A medicinal product containing オファツムマブ（遺伝子組換え）, registered in Japan by ノバルティス ファーマ, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- オファツムマブ（遺伝子組換え）
- Manufacturer
- ノバルティス ファーマ
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
オファツムマブ（遺伝子組換え） in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKESIMPTANovartis Europharm Limited, Dublin
- BelgiumArzerra 100 mgNovartis Europharm
- FinlandArzerraNovartis Europharm Limited
- United KingdomArzerra 1000mg/50ml concentrate for solution for infusion vialsNovartis Pharmaceuticals UK Ltd
- SpainKESIMPTA 20 mg SOLUCION INYECTABLE EN PLUMA PRECARGADANovartis Europharm Limited
- IrelandKesimpta 20 mg solution for injection in pre-filled penNovartis Europharm Limited
- IcelandKesimptaNovartis Europharm Limited*
- NetherlandsKesimpta 20 mg, oplossing voor injectie in voorgevulde penNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kesimpta
- Liechtenstein · Kesimpta
- Norway · Kesimpta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a7d8f411-84ab-46b5-8fd1-645034061abc GET /v1/drugs/a7d8f411-84ab-46b5-8fd1-645034061abc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２０ｍｇ０．４ｍＬ１キット",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1190405G1024",
"category": "注射薬",
"price_yen": 230860,
"generic_name": "オファツムマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "1190",
"transitional_expiry": null
}See everything about オファツムマブ（遺伝子組換え）.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.